A treatment developed by BridgeBio for an increasingly common heart disease missed its primary endpoint in a closely watched trial, the company said Monday, derailing its plans and prolonging the development of what experts considered a promising new drug.
Patients treated with the drug, called acoramidis, performed no better than those on a placebo on a test of how far they could walk over the course of six minutes. BridgeBio enrolled about 600 patients with ATTR-CM, a progressive heart disease. After 12 months, patients who got acoramidis could walk nine meters fewer, and patients on placebo walked seven meters fewer.
“This result is disappointing and baffling,” BridgeBio CEO Neil Kumar said in a statement. “I am, along with many others, searching for answers” regarding the six-minute walk test.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
